688073 Stock Overview
Engages in the research, development, production, and sale of pharmaceutical products in China. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 2/6 |
Bide Pharmatech Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥41.70 |
52 Week High | CN¥65.92 |
52 Week Low | CN¥28.50 |
Beta | 0.80 |
11 Month Change | 23.15% |
3 Month Change | 36.19% |
1 Year Change | -34.75% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -13.40% |
Recent News & Updates
Shareholder Returns
688073 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | -4.7% | -4.0% | -3.9% |
1Y | -34.8% | -5.3% | 4.0% |
Return vs Industry: 688073 underperformed the CN Pharmaceuticals industry which returned -5.3% over the past year.
Return vs Market: 688073 underperformed the CN Market which returned 4% over the past year.
Price Volatility
688073 volatility | |
---|---|
688073 Average Weekly Movement | 9.8% |
Pharmaceuticals Industry Average Movement | 7.2% |
Market Average Movement | 8.2% |
10% most volatile stocks in CN Market | 12.5% |
10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 688073 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688073's weekly volatility (10%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 809 | Lan Dai | www.bidepharmatech.com |
Bide Pharmatech Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. The company’s products are used in life sciences, organic chemistry, materials science, analytical chemistry, and other applications. The company was incorporated in 2007 and is headquartered in Shanghai, China.
Bide Pharmatech Co., Ltd. Fundamentals Summary
688073 fundamental statistics | |
---|---|
Market cap | CN¥3.68b |
Earnings (TTM) | CN¥80.03m |
Revenue (TTM) | CN¥1.10b |
46.0x
P/E Ratio3.4x
P/S RatioIs 688073 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
688073 income statement (TTM) | |
---|---|
Revenue | CN¥1.10b |
Cost of Revenue | CN¥669.54m |
Gross Profit | CN¥428.69m |
Other Expenses | CN¥348.66m |
Earnings | CN¥80.03m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.91 |
Gross Margin | 39.03% |
Net Profit Margin | 7.29% |
Debt/Equity Ratio | 2.9% |
How did 688073 perform over the long term?
See historical performance and comparison